Antibody and antigen responses to Ensovibep vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. by Elizabeth S. Munroe (21568166)

Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. by Elizabeth S. Munroe (21568166)

Antibody and antigen responses after treatment with nMAb vs placebo, day 1-90 (pooled nMAb treatments). by Elizabeth S. Munroe (21568166)

Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. by Elizabeth S. Munroe (21568166)

Antibody and antigen responses by baseline anti-spike neutralizing response assay positivity. by Elizabeth S. Munroe (21568166)

Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis). by Elizabeth S. Munroe (21568166)

Daily PCR-confirmed COVID-19 cases (top). by Diego Casas-Deza (11819838)

Ribosomal subunit pathways are decreased in <i>Resf1</i> knockdown cells. by Megan R. Majocha (18529925)

“…<p>(A) GO Pathway analysis snapshots of various ribosomal subunit pathways that are decreased in 6DT1 <i>Resf1</i> KD cells. (B) The GO Cytosolic Ribosome pathway had many (C) small and large ribosomal proteins decreased in <i>Resf1</i> KD cells. …”

Long-term anti-nucleocapsid response by baseline patient characteristics. by Elizabeth S. Munroe (21568166)

Excessive LF4A kinase activity shortens cilia and decreases IFT. by Yu-Yang Jiang (7036916)

The introduction of mutualisms into assembled communities increases their connectance and complexity while decreasing their richness. by Gui Araujo (22170819)

“…When they stop being introduced in further assembly events (i.e. introduced species do not carry any mutualistic interactions), their proportion slowly decreases with successive invasions. (B) Even though higher proportions of mutualism promote higher richness, introducing this type of interaction into already assembled large communities promotes a sudden drop in richness, while stopping mutualism promotes a slight boost in richness increase. …”

Projected change in large copepod biomass between 2003–2012 and 2030–2039 for the (a) MIROC and (b) CGCM models. by Melanie A. Smith (300377)

Daily confirmed COVID-19 cases (n = 61,993) and smoothed trends for the median age of all the cases, hospitalized cases, and deceased cases. by Diego Casas-Deza (11819838)

cGAS activation is suppressed by Olaparib, resulting in the suppression of cellular migration. by Mafuka Suzuki (14515529)

HbA1c for new and previous diabetes diagnoses at start of TB treatment by TB treatment regimen. by Sharon E. Cox (7243847)

Subjects:

Position of residues 138, 153, 477 and 675 in the spatial structure of the S protein bound with 4A8 and 4–59 antibodies (PDB IDs: 7c2l and 7czx). by Galya V. Klink (10031952)

Subjects:

Table 1_Association of dynamic changes in metabolic syndrome components with clinical outcomes in diffuse large B-cell lymphoma.docx by Dewan Zhao (21547445)

“…Introduction<p>Diffuse Large B-Cell Lymphoma (DLBCL) is the most common subtype of Non-Hodgkin Lymphoma (NHL), with 20-40% of patients experiencing poor outcomes despite advancements in treatment. …”

Association of SDOH scores with attitudes, practices and mental health outcomes among Arkansans overall and by race and ethnicity ^a^,^b^,<s... by Jenil R. Patel (3639451)